Fig. 1
From: Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma
Workflow chart of data generation and diagnosis analysis. ELSA-seq panel 85,250 CpG sites were applied to a training cohort of 15 normal liver tissue, 17 liver cirrhotic tissue, 31 HCC tissue (19 stage 0-A, 4 stage B, 7 stage C, and 1 stage D) to identify a final selection of 2321 differentially methylated markers. These markers were applied to a training and cross-validation cohort and also a single-blind validation cohort.